Suppr超能文献

检测尿游离miR-210作为透明细胞肾细胞癌液体活检的潜在工具。

Detection of urinary cell-free miR-210 as a potential tool of liquid biopsy for clear cell renal cell carcinoma.

作者信息

Li Guorong, Zhao An, Péoch Michel, Cottier Michèle, Mottet Nicolas

机构信息

Department of Urology, North Hospital, CHU of Saint-Etienne, University of Jean-Monnet, Saint-Etienne, France; Inserm U1059, Saint-Etienne, France.

Zhejiang Cancer Research Institute, Zhejiang Province Cancer Hospital, Hangzhou, China.

出版信息

Urol Oncol. 2017 May;35(5):294-299. doi: 10.1016/j.urolonc.2016.12.007. Epub 2017 Jan 12.

Abstract

BACKGROUND

Recent findings show that cell-free miRNAs are stable in biological fluid. Urine provides an alternative to blood serum or plasma as a potential source of tumor biomarkers. MiR-210 is proven to be overexpressed in patients with a clear cell renal cell carcinoma (ccRCC). The purpose of this pilot study was to examine the urinary cell-free miR-210 as a potential tool of liquid biopsy for ccRCC.

METHODS

Overall, 75 patients with a ccRCC and 45 control subjects without a cancer were included in this study. Urine samples were centrifuged twice and the cell-free urine supernanants were stored in -80°C until use. A total of 350µl cell-free urine was used for the extraction of total RNA. The expression levels of these miRNAs were performed by using quantitative RT-PCR.

RESULTS

The level of urinary cell-free miR-210 was significantly higher in patients with ccRCC than in control subjects (P<0.001). The urinary cell-free miR-210 yielded the areas under the receiver operating characteristics curve of 0.76 in discriminating the patients with ccRCC from the control subjects with a sensitivity of 57.8% and a specificity of 80.0%. Moreover, the expression level of urinary cell-free miRNA-210 was significantly decreased in the patients a week after surgery (P<0.001).

CONCLUSION

Urinary cell-free miR-210 may be used as a potential tool of liquid biopsy for ccRCC diagnosis. Further studies are needed to confirm our results.

摘要

背景

最近的研究结果表明,游离微小RNA(miRNAs)在生物体液中是稳定的。尿液可作为血清或血浆的替代物,成为肿瘤生物标志物的潜在来源。已证实miR-210在透明细胞肾细胞癌(ccRCC)患者中过表达。本初步研究的目的是检测尿液游离miR-210作为ccRCC液体活检的潜在工具。

方法

本研究共纳入75例ccRCC患者和45例无癌症的对照受试者。尿液样本离心两次,将游离尿液上清液储存在-80°C直至使用。总共350µl游离尿液用于提取总RNA。使用定量逆转录聚合酶链反应(RT-PCR)检测这些miRNAs的表达水平。

结果

ccRCC患者尿液中游离miR-210的水平显著高于对照受试者(P<0.001)。尿液游离miR-210在区分ccRCC患者与对照受试者时,受试者工作特征曲线下面积为0.76,灵敏度为57.8%,特异性为80.0%。此外,术后一周患者尿液中游离miRNA-210的表达水平显著降低(P<0.001)。

结论

尿液游离miR-210可作为ccRCC诊断的潜在液体活检工具。需要进一步研究来证实我们的结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验